FDA Gets One Step Closer to Protecting Consumers
According to an article in today's LA Times, next week the FDA has scheduled a two-day meeting to determine the future of the popular diabetes pill, Avandia.
The GlaxoSmithKline pharmaceutical, which is still on the market, has been linked to dangerous side-effects such as heart attack and death. Consumers who have been affected by the drug are getting closer to receiving compensation for their damages, but the fight is still far from over.
This highly controversial pharmaceutical treats type II diabetes, which affects nearly 20 million Americans. Studies by such organizations as the Journal of the American Medical Association are reporting on dangers of increased chances of cardiovascular threats from using Avandia over other diabetes drugs.
